Results 111 to 120 of about 16,947 (261)

Cristid obliqua morphology as a correlate of diet in lorisoids

open access: yesThe Anatomical Record, EarlyView.
Abstract Methods for elucidating dietary patterns from dental morphology have provided much insight into molar form, function, and diet in extinct taxa. However, many methods rely on the collection of homologous landmarks (like shearing crest lengths), or computationally intensive and nuanced metrics that capture shape (like dental topography). Here, a
Keegan R. Selig
wiley   +1 more source

First evidence of a mandibular crest in Brasileodactylus Kellner, 1984 (Pterosauria, Pteranodontoidea, Anhangueridae), with comments on pterosaur headcrests

open access: yesThe Anatomical Record, EarlyView.
Abstract Brasileodactylus araripensis Kellner, 1984, is a toothed pterosaur from the Lower Cretaceous Romualdo Formation of the Araripe Basin, Brazil. Traditionally regarded as crestless, the species has been central to debates on anhanguerid taxonomy, as most members of the clade possess well‐developed sagittal cranial or dentary crests.
Anderson da Silva Nascimento   +4 more
wiley   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis   +5 more
wiley   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl   +14 more
wiley   +1 more source

Butorphanol Pharmacokinetics Across Species: Meta‐Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Butorphanol, an opioid agonist–antagonist used in human and veterinary medicine, lacks systematic interspecies comparisons. Butorphanol pharmacokinetics (PK) was assessed across species using a minimal physiologically based PK (mPBPK) model and ...
Ahmed M. Saeed, William J. Jusko
doaj   +1 more source

Extrapolation and pharmacokinetic protocol design optimization for ceftriaxone as an exemplar for the development of antibiotics for children

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Ceftriaxone is a cephalosporin commonly used for the treatment of acute, severe infections; however, there are conflicting data on its disposition properties in children, making it a suitable case study for the evaluation of the appropriateness of extrapolation approaches based on exposure matching principles for paediatric patients and exploring ...
Daniel Valente Neves   +7 more
wiley   +1 more source

Pharmacometric evaluation of pre‐referral rectal artesunate in children with severe malaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Parenteral artesunate is the preferred first‐line treatment for severe malaria. Pre‐referral rectal artesunate suppositories are recommended where parenteral treatment is inaccessible. In this study, we compared dihydroartemisinin exposure and model‐predicted early parasite clearance following rectal artesunate and intravenous artesunate in ...
Ayorinde Adehin   +6 more
wiley   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor   +12 more
wiley   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara   +20 more
wiley   +1 more source

Model‐Informed Evaluation of Hydroxyurea Exposure During Lactation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Hydroxyurea is a cornerstone therapy for sickle cell anemia; however, evidence guiding its use during lactation remains limited. This study aimed to develop a population pharmacokinetic (PK) model to characterize hydroxyurea disposition in maternal plasma and breast milk, and to quantify infant exposure under clinically relevant breastfeeding scenarios.
Anhar Hosawi   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy